Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
نویسندگان
چکیده
BACKGROUND Costly biologicals in palliative oncology are emerging at a rapid pace. For example, in patients with advanced esophageal squamous cell carcinoma addition of cetuximab to a palliative chemotherapy regimen appears to improve survival. However, it simultaneously results in higher costs. We aimed to determine the incremental cost-effectiveness ratio of adding cetuximab to first-line chemotherapeutic treatment of patients with advanced esophageal squamous cell carcinoma, based on data from a randomized controlled phase II trial. METHODS A cost effectiveness analysis model was applied based on individual patient data. It included only direct medical costs from the health-care perspective. Quality-adjusted life-years and incremental cost-effectiveness ratios were calculated. Sensitivity analysis was performed by a Monte Carlo analysis. RESULTS Adding cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced esophageal squamous cell carcinoma resulted in an the incremental cost-effectiveness ratio of €252,203 per quality-adjusted life-year. Sensitivity analysis shows that there is a chance of less than 0.001 that the incremental cost-effectiveness ratio will be less than a maximum willingness to pay threshold of €40,000 per quality-adjusted life-year, which is representative for the threshold used in The Netherlands and other developed countries. CONCLUSIONS Addition of cetuximab to a cisplatin-5-fluorouracil first-line regimen for advanced esophageal squamous cell carcinoma is not cost-effective when appraised according to currently accepted criteria. Cost-effectiveness analyses using outcome data from early clinical trials (i.c. a phase II trial) enable pharmaceutical companies and policy makers to gain early insight into whether a new drug meets the current eligibility standards for reimbursement and thereby potential admittance for use in regular clinical practice.
منابع مشابه
Detection of Human Papillomavirus DNA by PCR in Esophageal Squamous Cell Carcinoma from Turkmen Sahra, North-East of Iran
Human papillomavirus (HPV) DNA has been identified in esophageal carcinomas. However, the incidence of HPV varies significantly in different geographical locations. In this study, neoplasms from Turkmen Sahra, a region in Golestan province in northeast part of Iran, with a high incidence of squamous cell carcinoma were analyzed for the presence of HPV DNA. Turkmen Sahra is located in the cancer...
متن کاملDetection of Human Papillomavirus in Osophageal Squamous Cell Carcinoma samples in Mazandaran Province, Iran
We examined 170 formalin-fixed paraffin-embedded samples from esophageal squamous cell carcinoma patients. All subjects live in Mazandaran province, a region with high incidence rate of esophageal cancer and have become known as the “Asian Esophageal Cancer Belt”. Samples were tested for HPV-DNA by MY09/11 and Gp5+/6+ general primers using nested PCR. Of the 170 ESCC samples, 86 (50.6%) were ma...
متن کاملThe Prevalence of Human Papilloma Virus in Esopha-geal Squamous Cell Carcinoma
Background: Carcinomas of esophagus, mostly squamous cell carcinomas, occur throughout the world. There are a number of suspected genetic or environmental etiologies. Human papilloma virus (HPV) is said to be a major etiology in areas with high incidence of esophageal carcinoma, while it is hardly detectable in low incidence regions. This study was designed to evaluate the prevalence of HPV in ...
متن کاملAn economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.
OBJECTIVES A phase III randomized trial that compared the combination of cetuximab and radiotherapy to radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck provided a platform for a comprehensive economic evaluation. The study was conducted to estimate the cost-effectiveness of cetuximab in combination with radiotherapy compared to radiotherapy alone...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2016